OraSure Technologies up 19% on Positive FDA Recommendation

OraSure Technologies

is trading higher on the session following its announcement yesterday that the company's in-home HIV test received a unanimous positive recommendation from the FDA advisory committee. Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies stated: "We are pleased with the outcome of today's Blood Products Advisory Committee meeting. There was broad support expressed by the HIV community at today's meeting and we look forward to continuing our work with them in the fight against HIV. We believe the OraQuick® In-Home HIV Test will make a valuable contribution in this fight." OraSure Technologies is currently trading at $10.83, a gain of $1.73 or 19.01%.